Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M

INTEGRATED BIOPHARMA INC

2023-Q3 EPS reported $0.00 revenue$37,678,000

Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.
Operating income $44K vs $1.0M; net income $16K ($0.00 EPS) vs $0.8M ($0.03 EPS).
Nine-month net loss $74K vs net income $2.3M in prior year.
Two largest customers fell from 91% to 88% of revenue; overstocking during pandemic cited as cause.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTEGRATED BIOPHARMA INC reported financial results for the three and nine months ended March 31, 2023.

Period: the three and nine months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-23-013899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.